Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Antengene Announces Submission of IND Application in China for a Global Phase 3 Trial of ATG-010 (Selinexor) in Advanced or Recurrent Endometrial Cancer

prnasiaJanuary 05, 2021

Tag: Antengene , ATG-010 , Endometrial Cancer , SIENDO

PharmaSources Customer Service